HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Agrawal, N. G. B. Articles by Gottesdiener, K. M. Search for Related Content PubMed PubMed Citation Articles by Agrawal, N. G. B. Articles by Gottesdiener, K. M. Social Bookmarking                         What's this?

Pharmacokinetics of Etoricoxib in Patients with Renal Impairment

From Merck Research Laboratories, West Point, Pennsylvania (Dr. Agrawal, Ms. Matthews, Mr. Mazenko, Mr. Kline, Dr. Woolf, Dr. Porras, Ms. Geer); Merck Research Laboratories, Rahway, New Jersey (Ms. Wong, Dr. Cho, Ms. Cote, Dr. Schwartz, Dr. Gottesdiener); Merck Research Laboratories, Blue Bell, Pennsylvania (Dr. Petty); Orlando Clinical Research Center, Orlando, Florida (Dr. Marbury); PPD Development, Inc., Austin, Texas (Dr. Moncrief); Total Renal Research, Inc., Minneapolis, Minnesota (Dr. Alcorn, Dr. Swan); Radiant Research-Austin, Austin, Texas (Dr. Sack); and Christchurch Clinical Studies Trust, Christchurch, New Zealand (Dr. Robson).

The effect of renal insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was examined in 23 patients with varying degrees of renal impairment (12 moderate [creatinine clearance between 30 and 50 mL/min/1.73 m²], 5 severe [creatinine clearance below 30 mL/min/1.73 m²], and 6 with end-stage renal disease requiring hemodialysis) following administration of single 120-mg oral doses of etoricoxib. Even the most severe renal impairment was found to have little effect on etoricoxib pharmacokinetics. The low recovery of etoricoxib in dialysate (less than 6% of the dose) supports that hemodialysis also has little effect on etoricoxib pharmacokinetics, and binding of etoricoxib to plasma proteins was generally unaffected by renal disease. Single doses of etoricoxib were generally well tolerated by patients with renal impairment. Based on pharmacokinetic considerations, dosing adjustments are not necessary for patients with any degree of renal impairment. However, because patients with advanced renal disease (creatinine clearance below 30 mL/min/1.73 m²) are likely to be very sensitive to any further compromise of renal function, and there is no long-term clinical experience in these patients, the use of etoricoxib is not recommended in patients with advanced renal disease.

Key Words: Etoricoxib • pharmacokinetics • renal impairment • bioavailability • cyclooxygenase • COX-2

Address for reprints: Dr. Nancy G. B. Agrawal, Department of Drug Metabolism, WP75-200, Merck Research Laboratories, West Point, PA 19486.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. D Martina, K. S Vesta, and T. L Ripley Etoricoxib: A Highly Selective COX-2 Inhibitor Ann. Pharmacother., May 1, 2005; 39(5): 854 - 862. [Abstract] [Full Text] [PDF]